Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Personalized Medicine and Imaging

Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer

Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Xin Hu, Ke-Da Yu and Zhi-Ming Shao
Yi-Rong Liu
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
2Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Zhou Jiang
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
2Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao-En Xu
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
2Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Hu
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
2Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke-Da Yu
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
2Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhimingshao@yahoo.com yukeda@163.com
Zhi-Ming Shao
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
2Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
4Institutes of Biomedical Sciences, Fudan University, Shanghai, P.R. China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhimingshao@yahoo.com yukeda@163.com
DOI: 10.1158/1078-0432.CCR-15-1555 Published April 2016
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: By integrating expression profiles of mRNAs and long noncoding RNAs (lncRNA), we tried to develop and validate novel multigene signatures to facilitate individualized treatment of triple-negative breast cancer (TNBC) patients.

Experimental Design: We analyzed 165 TNBC samples and 33 paired normal breast tissues using transcriptome microarrays. Tumor-specific mRNAs and lncRNAs were identified and correlated with patients' recurrence-free survival (RFS). Using Cox regression model, we built two multigene signatures incorporating mRNAs and lncRNAs. The prognostic and predictive accuracy of the signatures were tested in a training set of 165 TNBC patients and validated in other 101 TNBC patients.

Results: We successfully developed an mRNA and an integrated mRNA–lncRNA signature based on eight mRNAs and two lncRNAs. In the training set, patients in the high-risk group were more likely to suffer from recurrent disease than patients in the low-risk group in both signatures [HR, 10.00; 95% confidence interval (CI), 2.53–39.47, P = 0.001; HR = 4.46, 95% CI, 1.34–14.91, P = 0.015 for integrated signature and mRNA signature, respectively). Results were validated in the validation set (P = 0.019 and 0.030, respectively). In addition, time-dependent receiver operating curve showed that the integrated mRNA–lncRNA signature had a better prognostic value than both the eight-mRNA-only signature and the clinicopathologic risk factors in both sets. We also found through interaction analysis that patients classified into the low-risk group by the integrated mRNA–lncRNA signature had a more favorable response to adjuvant taxane chemotherapy.

Conclusions: The multigene signature we developed can accurately predict clinical outcome and benefit of taxane chemotherapy in TNBC patients. Clin Cancer Res; 22(7); 1653–62. ©2016 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • Received June 30, 2015.
  • Revision received November 5, 2015.
  • Accepted November 12, 2015.
  • ©2016 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 22 (7)
April 2016
Volume 22, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Xin Hu, Ke-Da Yu and Zhi-Ming Shao
Clin Cancer Res April 1 2016 (22) (7) 1653-1662; DOI: 10.1158/1078-0432.CCR-15-1555

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Xin Hu, Ke-Da Yu and Zhi-Ming Shao
Clin Cancer Res April 1 2016 (22) (7) 1653-1662; DOI: 10.1158/1078-0432.CCR-15-1555
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Disclaimer
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • IDH1 Mutation Analyzed by Vibrational Spectroscopy
  • Biomimetic Strategies to Improve CTC Capture
  • E2F4 Activity Mediates Resistance to Antiestrogen Therapy
Show more Personalized Medicine and Imaging
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement